Signature Diagnostics AG to Present Detector C 2.0 - A Blood Test for Early Detection of Colorectal Cancer at the American Society of Clinical Oncology 2012 Gastrointestinal Cancer Symposium in San Francisco

POTSDAM, GERMANY--(Marketwire - January 20, 2012) -

Signature Diagnostics / Signature Diagnostics to Present Detector C 2.0 - A Blood Test for Early Detection of Colorectal Cancer at the ASCO 2012 Gastrointestinal Cancer Symposium in San Francisco . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Potsdam, Germany, January 20, 2012 - Signature Diagnostics AG announced today that the company was selected to present its improved test -Detector C 2.0 for early detection of colorectal cancer (CRC) at the ASCO 2012 Gastrointestinal Cancer Symposium in San Francisco on January 19-21, 2012.

The paper, “Detector-c 2.0: A highly accurate blood-based IVD test for early detection of colorectal cancer with sensitivity and specificity over 90%.” will be presented at the General Poster Session C on Cancers of the Colon and Rectum, January 21, 2012, 8:00am-9:00am and 12:00-1:30pm.

Detector C 2.0 is an improved version of the Detector C test. It measures a panel of 1.000 RNA markers in whole blood. Detector C 2.0 is based on a set of 445 patients of which 291 patients were cases with confirmed CRC of all four stages, and 154 were healthy controls seeking a screening colonoscopy and underwent complete colonoscopy. Detector C 2.0 has a sensitivity of 91.6% and a specificity of 94.8%. Sensitivity of high-grade intraepithelial neoplasias (high-grade adenoma) was 67%. Detector C 2.0 is based on a 3-times larger patient set and shows an increase in sensitivity and specificity over Detector C of 1.6% and 6.8%, respectively.

Signature Diagnostics AG is a molecular diagnostics company based in Potsdam, Germany, focusing on the development and commercialization of novel molecular oncology diagnostic products for early detection (screening) and prognosis of cancer. The company has completed development of its first two diagnostic products for colorectal cancer screening (“Detector C/C+") and prognosis (“Predictor C”), which will be launched in 2012 in its own ISO 15189 certified service laboratory. Using its state-of-the-art technologies in tissue and blood sample collection, molecular pathology, Xenopatient™ platform, genome-wide profiling, data mining, and biostatistics, the company collaborates with clinical, pharmaceutical, and diagnostic partners. Signature Diagnostics sponsors and conducts large prospective, multicenter clinical trials with more than 33 primary care hospitals and several dozen colonoscopy centers in Germany to discover and validate biomarkers in oncology.

Press release (PDF): http://hugin.info/143237/R/1579139/492701.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Signature Diagnostics via Thomson Reuters ONE

[HUG#1579139]